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Abstract. The present study aimed to evaluate the molecular 
mechanisms underlying combinatorial bone marrow stromal 
cell (BMSC) transplantation and chondroitinase ABC 
(Ch-ABC) therapy in a model of acellular nerve allograft 
(ANA) repair of the sciatic nerve gap in rats. Sprague 
Dawley rats (n=24) were used as nerve donors and Wistar 
rats (n=48) were randomly divided into the following groups: 
Group I, Dulbecco's modified Eagle's medium (DMEM) 
control group (ANA treated with DMEM only); Group II, 
Ch-ABC group (ANA treated with Ch-ABC only); Group III, 
BMSC group (ANA seeded with BMSCs only); Group IV, 
Ch-ABC + BMSCs group (Ch-ABC treated ANA then seeded 
with BMSCs). After 8 weeks, the expression of nerve growth 
factor, brain-derived neurotrophic factor and vascular endo-
thelial growth factor in the regenerated tissues were detected 
by reverse transcription-quantitative polymerase chain reac-
tion and immunohistochemistry. Axonal regeneration, motor 
neuron protection and functional recovery were examined by 
immunohistochemistry, horseradish peroxidase retrograde 
neural tracing and electrophysiological and tibialis anterior 
muscle recovery analyses. It was observed that combination 
therapy enhances the growth response of the donor nerve 
locally as well as distally, at the level of the spinal cord moto-
neuron and the target muscle organ. This phenomenon is likely 
due to the propagation of retrograde and anterograde transport 
of growth signals sourced from the graft site. Collectively, 
growth improvement on the donor nerve, target muscle and 
motoneuron ultimately contribute to efficacious axonal regen-
eration and functional recovery. Thorough investigation of 
molecular peripheral nerve injury combinatorial strategies are 
required for the optimization of efficacious therapy and full 
functional recovery following ANA.
Introduction
Despite several decades of research, peripheral nerve injury 
(PNI) repair remains suboptimal, as full recovery is difficult 
to achieve (1). Nerve autografting remains the gold standard 
in PNI therapy (2); however, autografting may be a clinical 
challenge due to the creation of a secondary injury site and the 
limited availability of donor graft resources. Peripheral nerve 
allografts have proved efficacious in the treatment of nerve 
injury, and thus provide a viable alternative to the challenges 
of autografting (3). Nerve allografts have been demonstrated to 
preserve the extracellular environment of the injury site (4,5), 
as well as promoting a favorable environment for local neuro-
trophic factors to aid in axonal regeneration (6), collectively 
aiding the biocompatibility of the technique. Though prom-
ising, over the previous few decades it has become clear that 
microsurgical approaches themselves cannot fully reconcile 
the complex nature of PNI. For this purpose, combinatorial 
strategies, which employ microsurgical and biological manip-
ulations in tandem (such as neurotrophic factors, extracellular 
matrix components, over-riding inhibitory cues and cell trans-
plantation), have been increasingly investigated (7,8). 
Coupling allografts with growth-enhancing factors has 
demonstrated improved outcomes compared with unassisted 
nerve grafts. For example, allografts of the sciatic nerve, when 
combined with brain-derived neurotrophic factor (BDNF) 
scaffolding, increased neuronal regeneration in a model of rat 
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spinal cord injury (9). Similarly, stem cell transplantation is 
also able to aid PNI recovery, likely due to the multipotent 
differentiation potential and successful integration into host 
systems of stem cells, without the need for immunosuppres-
sion (10). Bone mesenchymal stem cells (BMSCs) in particular 
have been demonstrated to aid the regeneration of sciatic nerve 
injury (11). Previously, we demonstrated that BMSC transplan-
tation combined with chondroitinase ABC (an axonal growth 
inhibitor-cleaving enzyme) during peripheral nerve allograft 
enhanced axonal regeneration and functional recovery in a 
rat model of sciatic nerve injury (12). In general, combinato-
rial therapies that have been assessed appear to supersede 
the efficacy of various isolated techniques (7). However, the 
mechanisms underlying these intervention strategies at the 
molecular level have yet to be elucidated. Uncovering such 
strategies is paramount to the optimization of combinatorial 
therapies and the reduction of adverse outcomes. Herein, 
we aimed to explore the mechanistic underpinnings of 
BMSCs and Ch-ABC-assisted acellular allografts on axonal 
regeneration in peripheral nerve injury. Using a rat model 
of sciatic nerve gap repair [acellular nerve allograft (ANA)], 
the cellular, molecular and functional profiles of spinal cord 
motoneurons, donor nerve, and target tissues were evaluated 
in order to comprehensively assess the biological outcomes 
of this combinatorial therapy. The current study describes the 
direct enhancement of axonal regeneration at the graft site, 
as well as growth enhancement on spinal cord motoneurons 
and target organs. These are likely the result of the retro- and 
anterograde propagation of growth signals sourced from the 
donor nerve, working in unison to improve observed func-
tional outcomes. The current study reveals a number of the 
molecular contributors to the therapeutic success of BMSCs 
and Ch-ABC assisted ANA contributions that may serve as 
targets for greater investigation and optimization in the future. 
Materials and methods
Animals. Healthy Wistar rats (n=48, including 24 male and 
24 female) and Sprague-Dawley (SD) rats (n=24, including 
12 male and 12 female) weighing 180-220 g were provided by 
the Experimental Animal Center of China Medical University 
(Shenyang, China; cert no. SCXK Liao 2008-0005). SD 
rats were used as nerve donors and Wistar rats were used as 
graft recipients. The rats were housed in a temperature- and 
humidity-controlled environment under a 12-h light/dark 
cycle, with ad libitum access to food and water. The animals 
were housed separately. The present study was approved by the 
Experimental Animal Administration and Ethics Committee 
of China Medical University.
Preparation and treatment of ANA. ANA were prepared by a 
hypotonic chemical detergent method described previously (8). 
On the day prior to surgery, ANA were incubated with either 
100 µl phosphate buffered saline (PBS; pH 7.4) containing 
2 U/ml Ch-ABC (Sigma-Aldrich, St. Louis, MO, USA) or with 
PBS alone (vehicle) for 16 h at 37˚C. The grafts were rinsed 
twice with PBS and stored on ice prior to use. 
Preparation of BMSCs. Bone marrow was aspirated with a 
disposable needle from the femurs of rats sacrificed by CO2 
overdose for preparation of ANA. The cells were collected 
in heparinized syringes following a previously described 
protocol (13). Briefly, femurs were removed, cleaned of muscle 
and connective tissue, and bone marrow was flushed out with 
PBS. Following centrifugation at 1,000 x g for 5 min at 4˚C, 
the supernatant was discarded and the cells were re-suspended 
in complete medium containing Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS; Hyclone; GE Healthcare Life Sciences, Logan, UT, 
USA), 100 U/ml penicillin and 100 U/ml streptomycin at 37˚C 
and 5% CO2. Following incubation of the dissociated cells 
for 24 h at 37˚C, the non‑adherent cells were removed. The 
adherent cells were continuously cultured at 37˚C in 5% CO2, 
and then used for the subsequent experiments. In all experi-
ments, cells were used at passages II–IV.
Preparation of ANA seeded with BMSCs. BMSCs were 
harvested with 0.25% trypsin (Hyclone; GE Healthcare Life 
Sciences) and suspended in complete medium at a density of 
2x107 cells/ml. A total of 2x107 BMSCs in 100 µl complete 
medium were injected into four evenly spaced points of the 
nerve section using a micro-injector under an SXP-10 micro-
scope (magnification, x10; Shanghai Medical Equipment 
Works Co., Ltd., Shanghai, China). The nerve grafts were then 
incubated in complete medium in a humidified atmosphere 
containing 5% CO2 at 37˚C for 48 h, after which they were 
collected for in vivo experiments.
Scanning electron microscopy (SEM) analysis. BMSC adhe-
sion to donor ANA was assessed via SEM analysis. Grafts 
were fixed for 24 h in 4% glutaraldehyde in 0.1 M PBS. The 
scaffolds were further rinsed in deionized water, and dehy-
drated with a graded series of ethanol solutions (50, 70, 90, 
100%; 10 min each). Finally, the scaffold was treated with 
hexamethyldisilazane (Sigma-Aldrich) and air-dried in a 
fume hood overnight. The specimens were mounted on stubs 
and sputter coated with gold, loaded into a scanning electron 
microscope (S3400N; JEOL, Ltd., Tokyo, Japan), and viewed 
under an accelerating voltage of 5 kV.
Additionally, some ANAs were embedded in 1.5% (w/v) 
agarose (Sigma-Aldrich), fixed in 2% (v/v) glutaraldehyde 
(Sigma‑Aldrich) in 0.1 M phosphate buffer (pH 7.2), post‑fixed 
with 1% (w/v) osmium tetroxide (Sigma-Aldrich), dehydrated 
in a series of ascending ethanol concentrations, and embedded 
in epon 812 (Sigma-Aldrich). Ultrathin sections (60 nm) were 
collected on formvar-coated grids, post-stained with lead 
citrate and uranyl acetate, and subsequently imaged using 
electron microscopy (JEOL 1010; JEOL, Ltd.).
Surgical procedures. All Wistar rats were randomly divided 
into four groups (n=12/group) as follows: Group I, DMEM 
control group (ANA incubated in DMEM only); Group II, 
Ch-ABC group (ANA incubated in Ch-ABC only); Group III, 
BMSCs group (ANA seeded with BMSCs only); Group IV, 
Ch-ABC + BMSC group (Ch-ABC treated ANA then seeded 
with BMSCs). In all experiments, the DMEM group served as 
a negative control. Rats were anesthetized by intraperitoneal 
injection of 100 g/l chloral hydrate (350 mg/kg weight) and 
the right sciatic nerve was exposed, the nerve segment was 
sharply transected, allowed to retract, and then transected 
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again to bridge a 10-mm defect. The 1-cm acellular nerve 
grafts were stitched (four pins end-to-end) to bridge the two 
stumps of the nerve defects with 9-0 nylon sutures under an 
operation microscope (Fig. 1). The wounds of all rats were 
rinsed with 40,000 U gentamicin sulfates and muscle and skin 
were sutured. Following surgery, each rat was assigned an 
identification number and placed under a warm light, allowed 
to recover from anesthesia, and then housed separately with 
access to food and water in a colony room maintained at 
constant temperature (19‑22˚C) and humidity (40‑50%) with 
a 12-h light:dark cycle. No animals were lost to surgical or 
post-surgical complications. 
Immunohistochemistry. Briefly, serial 25 µm-thick frozen 
sections of the middle nerve graft were cut from each group 
(n=6) on a cryostat (Leica CM 3000; Leica Microsystems, Inc., 
Buffalo Grove, IL, USA), mounted on superfrost/plus slides 
(Menzel-Glaser, Braunschweig, Germany) and incubated 
with the following primary antibodies for 12 h at 4˚C: Goat 
anti-nerve growth factor (NGF) polyclonal antibody (1:200 
dilution; cat. no. N8773; Sigma-Aldrich), rabbit anti-BDNF 
polyclonal antibody (1:150 dilution; cat. no. SAB2108004; 
Sigma-Aldrich), rabbit anti-vascular endothelial growth 
factor (VEGF) monoclonal antibody (1:150 dilution; cat. 
no. ab51745; Abcam, Cambridge, MA, USA), rabbit-anti 
neuronal marker (NeuN) monoclonal antibody (1:200 dilution; 
cat. no. ab177487; Abcam), mouse anti-choline acetyltrans-
ferase (ChAT) monoclonal antibody (1:200 dilution; cat. 
no. AMAB91129; Sigma-Aldrich) and mouse-anti synap-
tophysin (SYP) monoclonal antibody (1:200 dilution; cat. 
no. S5768; Sigma-Aldrich). The immunoreactivity was visual-
ized by incubation with fluorescein isothiocyanate‑conjugated 
goat anti-mouse immunoglobulin (Ig)G (1:200 dilution; 
cat. no. F0257; Sigma-Aldrich), Texas Red-conjugated 
goat anti-rabbit IgG (1:200 dilution, cat. no. SAB3700888; 
Sigma-Aldrich) and CY5-conjugated goat anti-mouse IgG 
(1:200 dilution; cat. no. SAB4600397; Sigma-Aldrich) for 1 h 
at room temperature. A MetaMorph/DP10/BX41 analytical 
imaging system (Olympus Soft Imaging Solutions GmbH, 
Münster, Germany) was used to scan and generate figures. The 
integrated optical density (IOD) of positive immunological 
reactions was also analyzed using Image-Pro Plus 6.0 software 
(Media Cybernetics, Inc., Rockville, MD, USA). For each 
section, the positive IOD of five representative visual fields 
without overlap were observed under a high-power micro-
scope. 
The L4 spinal cord was positioned and removed by 
backward tracking of the repaired nerve. Homolateral tibialis 
anterior muscles were additionally removed from each group 
(n=6/group). The tissues were cut as 25 µm-thick frozen serial 
cross-sections. The sections were incubated in 3% H2O2 for 
10 min at room temperature then washed carefully with PBS 
three times (10 min each). The sections were blocked with 
5% bovine serum albumin (M B-Chem Corporation, Mumbai, 
India) for 30 min at 37˚C, then incubated at 4˚C overnight with 
rabbit anti-NF-200 polyclonal antibody (only for nerve graft; 
1:200 dilution; cat. no. N4142; Sigma-Aldrich), goat anti-NGF 
polyclonal antibody (1:150 dilution), rabbit anti-BDNF 
polyclonal antibody (1:100 dilution) or rabbit anti-VEGF 
monoclonal antibody (1:100 dilution). Subsequently, the tissue 
sections were washed three times in PBS, and then incubated 
with biotin-labeled goat anti-rabbit IgG (1:200 dilution; cat. 
no. ZDR-5118; Beijing Zhongshan Jinqiao Biotechnology Co., 
Ltd., Beijing, China) for 30 min at 37˚C, followed by incuba-
tion with streptavidin peroxidase complex (Beijing Zhongshan 
Jinqiao Biotechnology Co., Ltd.) for 30 min at 37˚C. Following 
washing with PBS and staining with 3,3-diaminobenzidine 
(Sigma-Aldrich) for 10 min, the tissue sections were observed 
under a light microscope (DM3000; Leica Microsystems 
GmbH, Wetzlar, Germany). The positively stained motoneu-
rons in the spinal cord anterior horn were counted, and the 
integrated optical density of positively stained nerves and 
muscles was analyzed using an analytical imaging system 
(Olympus Soft Imaging Solutions GmbH).
Reverse transcription‑quantitative polymerase chain 
reaction (RT‑qPCR). Total RNA was extracted from the 
nerve graft, spinal cord and muscles using TRIzol reagent 
(Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, 
USA) according to the manufacturer's protocol (n=6/group). 
Purified RNA was diluted to 500 ng/µl and 3 µl RNA was 
used to synthesize cDNA with a Prime Script RT reagent kit 
Table I. Primer sequences for quantitation of mRNA.
  Product
Gene Sequence size
NGF Forward: ACC TCT TCG GAC ACT CTG GA 168 bp
 Reverse: GTC CGT GGC TGT GGT CTT AT 
BDNF Forward: GGT CAC AGT CCT GGA GAA AG 214 bp
 Reverse: GTC TAT CCT TAT GAA CCG CC 
VEGF Forward: GGA CAT CTT CCA GGA GTA CC 147 bp
 Reverse: CGC ATG ATC TGC ATA GTG AC 
NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; 
VEGF, vascular endothelial growth factor.
Figure 1. ANA of rat sciatic nerve gap. ANAs (1 cm) were stitched to bridge 
both stumps of the rat sciatic nerve defects with 9-0 nylon sutures (black 
arrow) under an operation microscope. Scale bar=10 mm. ANA, acellular 
nerve allograft.
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(Takara Biotechnology Co., Ltd., Dalian, China). Primers 
were designed and synthesized by Takara Biotechnology 
Co., Ltd., and their sequences are displayed in Table I. 
RT-qPCR was performed using a SYBR Premix Ex Taq kit 
(Takara Biotechnology Co., Ltd.) according to the manufac-
turer's protocol for qPCR systems (ABI Prism 7000; Applied 
Biosystems; Thermo Fisher Scientific, Inc.). The amplification 
conditions were as follows: 30 sec at 95˚C (one cycle), 5 sec at 
95˚C and 30 sec at 60˚C (40 cycles) followed by 72˚C for 5 min 
(one cycle). RT-qPCR was performed three times in triplicate 
to evaluate the reproducibility of the data. The cycle number at 
which the amplification curve crossed the threshold line was 
noted as the critical quantification (Cq) and gene expression 
was calculated by the comparative Cq (2-ΔΔCq) method, using 
β-actin as the housekeeping gene for normalization.
Motoneurons, dendritic number and morphology. Eight 
weeks after injury, the rats were re-anesthetized and the left 
vastus lateralis muscle of the quadriceps was exposed and 
injected with horseradish peroxidase (HRP) conjugated to the 
cholera toxin B subunit (BHRP; 2 µl; 0.2%; List Biological 
Laboratories, Inc., Campbell, CA, USA). BHRP labeling 
permits population level quantitative analysis of motoneuron 
soma and dendritic morphology. Following BHRP injection 
[(48 h after, in order to ensure optimal labeling of motoneu-
rons (14,15)], the rats were weighed and received a lethal dose 
of Nembutal (45 mg/kg, i.p.; Sigma-Aldrich). The rats were 
subsequently perfused intracardially with saline followed by 
cold fixative solution (1% paraformaldehyde/1.25% glutaral-
dehyde), and then cut on a cryostat (40-µm-thick transverse 
sections for spinal cords). 
Motoneurons and dendritic lengths in a single representa-
tive set of alternate L4 spinal cord sections were measured 
under darkfield illumination initiated with the first section 
in which BHRP-labeled motoneurons and fibers were 
present. Labeling throughout the entire rostrocaudal extent 
of the quadriceps motoneuron dendritic field was assessed 
in each section using a computerized morphometry system 
(Neurolucida; MBF Bioscience, Inc., Williston, VT, USA) at a 
final magnification x250. No attempt was made to distinguish 
BHRP‑labeled fibers as either dendrites or axons. Average 
dendritic length per labeled motoneuron was estimated by 
totaling the measured dendritic lengths of the serial sections, 
multiplying by three to correct for sampling error, and then 
dividing by the total number of labeled motoneurons that was 
detected in that series (16). The length of labeled dendrites of 
motoneurons was assessed in sections 320 µm apart through 
the length of the lumbar spinal cord. A total of six rats were 
analyzed per group.
Electrophysiological analysis. Electrophysiological analysis 
was performed on the rats prior to sacrifice by CO2 over-
dose, using a Haishen NDI-200P1 electroneurogram device 
(Shanghai, China). The stimulus intensity was 1-20 mA to 
ensure a maximum waveform and to prevent independent 
muscle contractions. The stimulus duration was 0.1-0.2 msec, 
and the stimulation frequency was 1 Hz. Subsequently, 
with each animal under general anesthesia (pentobarbital; 
60 mg/ml i.p. injection; Sigma-Aldrich) the right sciatic nerve 
was exposed. A crook-shaped silver needle electrode was 
placed on the proximal and distal ends of the grafts, which 
were then stimulated at the distal end and recorded at the 
proximal end. The distance between the two electrodes was 
measured with a sliding caliper with 0.2 mm precision. Nerve 
conduction velocity, latency period and wave amplitude were 
then recorded in eight rats from each group.
Tibialis anterior muscle weights. The tibialis anterior muscles 
were dissected from both sides and detached from the bone 
at their origin and terminal point following electrophysi-
ological analysis, and weighed immediately with an electron 
scale to 0.0001 precision. The weight on the operated side was 
expressed as a percentage of the muscle weight on the unoper-
ated side.
Statistical analysis. All quantitative data were expressed as 
means ± standard deviation and analyzed with SPSS statis-
tical software (version 13.0; SPSS, Inc., Chicago, IL, USA). 
One-way analysis of variance followed by Dunnett's test 
was used for the comparison among experimental groups. 
Non-parametric data were compared using the Mann-Whitney 
U test among experimental groups. P<0.05 was considered to 
indicate a statistically significant difference.
Results
BMSC cultures and secreted growth factor. BMSCs appeared 
suspended in culture medium on day 1 and exhibited a small, 
spindle-like or fibroblast-like morphology on day 3. Cells 
reached 90% confluence on day 7. By the 3rd passage, BMSCs 
began to exhibit a whirlpool-like arrangement (Fig. 2A-D). After 
5 days of co-culture of BMSCs with DMEM or Ch-ABC-treated 
ANA, SEM observation revealed that BMSCs attach tightly 
to ANA irrespective of pretreatment with ANA (Fig. 2E-F). 
Subsequent to 5 days of co-culture, the growth factors NGF, 
BDNF and VEGF were investigated in pre-grafted ANA. 
Growth factors were detected at higher levels in the BMSC and 
Ch-ABC + BMSC groups compared with the DMEM group 
and Ch‑ABC groups. No significant difference was observed 
between the Ch-ABC group and the DMEM group, nor did the 
addition of Ch-ABC to BMSC seeded ANA appear to enhance 
the growth factor response (Fig. 2G), indicating that, at least 
pre-operatively, BMSCs are primarily responsible for the 
stimulation of growth on the donor nerve.
Combination treatment promotes axon regeneration. 
Immunohistochemical staining was performed for a nerve fiber 
marker (NF-200) in ANA in 4 and 8 week post-operative nerve 
recipients. It was revealed that the number of nerve fibers was 
significantly increased in all treatment groups compared with 
the DMEM negative control at 4 and 8 weeks (P<0.05; Fig. 3). 
Notably, the number of nerve fibers in the Ch‑ABC + BMSCs 
group was greater compared with the Ch-ABC and BMSC 
groups (P<0.05; Fig. 3). The aforementioned results indicate 
that combined BMSCs and Ch-ABC treatment promotes axonal 
regeneration at a greater capacity than any single treatment of 
the ANA 4-8 weeks after grafting.
Combination therapy promotes NGF, BDNF and VEGF 
expression in the regenerated tissues. Immunofluorescence 
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analysis revealed that in the centre of the ANA, NGF, BDNF 
and VEGF protein expression levels were increased in the 
BMSC and ChABC + BMSC groups compared with the 
DMEM and Ch-ABC groups (P<0.05; Fig. 4). Across all 
growth factors, the addition of Ch-ABC pre-treatment further 
increased the expression levels of the growth factors, compared 
with the BMSC group (P<0.05). Motoneurons of the L4 spinal 
cord anterior horn (Fig. 5) and target muscle tissue (Fig. 6) 
were similarly examined and resulted in similar growth factor 
expression patterns as the ANA (P<0.05). The immunohisto-
chemical data demonstrates the local and distal generation of 
growth factor responses primarily to BMSC seeding of the 
graft, with a level of additional enhancement due to Ch-ABC 
pre-treatment of the ANA.
Figure 2. BMSC culture and adherence to ANA. BMSCs were cultured at (A) day 1, (B) day 3, (C) day 7 and (D) at passage III (Scale bar=20 µm). SEM 
evaluation of BMSCs (black arrow) revealed (E) adhesion to the ANA and (F) Ch-ABC incubated ANA in vitro (Scale bar=10 µm). Analysis of NGF, BDNF 
and VEGF immunoreactivity in ANA sections was determined by integrated optical density. (G) NGF, BDNF and VEGF relative densities. n=6 per treatment 
condition. All data are expressed as means ± standard deviation. *P<0.05, vs. the DMEM group. ANA, acellular nerve allografts; SEM, scanning electron 
microscope; BMSC, bone marrow stromal cell; Ch‑ABC, chondroitinase ABC; DMEM, Dulbecco's modified Eagle's medium; NGF, nerve growth factor; 
BDNF, brain-derived neurotrophic factor; VEGF, vascular endothelial growth factor. 
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RT-qPCR analysis indicated that the comparative patterns 
of NGF, BDNF and VEGF mRNA expression levels in the 
ANA, L2-4 spinal cord and distal muscles were generally 
consistent with their comparative protein expression patterns. 
NGF, BDNF and VEGF mRNA expression levels in the BMSC 
group and Ch-ABC + BMSC group were higher compared 
with the DMEM and Ch-ABC groups (P<0.05) when ANA 
mRNA expression levels were analyzed (Fig. 7A). Spinal 
cord and muscle mRNA analysis indicated similar patterns 
of expression for BDNF, VEGF and NGF (Fig. 7B and C). 
Figure 3. Longitudinal assessment of post‑graft axonal regeneration. Immunohistochemical staining of neurofilament protein was performed in sections 
obtained from mid acellular nerve allograft from each group, collected at (A) 4 weeks (longitudinal section) and (B) 8 weeks (transverse section) (Scale 
bar=20 µm). (C) The number of nerve fibers. All data are expressed as the mean ± standard deviation; *P<0.05, vs. the DMEM group; #P<0.05, vs. the BMSC 
group; n=6 per group. BMSC, bone marrow stromal cell; Ch‑ABC, chondroitinase ABC; DMEM, Dulbecco's modified Eagle's medium.
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Detected across all tissues examined was the enhancement of 
the mRNA expression levels of NGF, BDNF and VEGF for the 
combined group BMSC + Ch-ABC compared with the BMSC 
group (P<0.05). Conclusively, the aforementioned results indi-
cate that combination therapy is able to increase growth factor 
protein and mRNA expression levels in the ANA, and across 
the distal spinal cord and target tissue sites. 
C o m b i n a t i o n  t h e ra p y  p ro t e c t s  m o t o n e u ro n s . 
Immunohistochemical staining was performed to detect the 
Figure 4. Immunohistochemical analysis of growth factor abundance in ANA 8 weeks after grafting. Immunohistochemical staining of (A) NGF, (B) BDNF 
and (C) VEGF in mid ANA sections across all treatment groups. Optical detection of immunoreactivity was achieved by green fluorescent reporter (Scale 
bar=20 µm). (D) Relative densities of immunoreactivity. All data are expressed as means ± standard deviation. *P<0.05, **P<0.01 vs. the DMEM group; 
#P<0.05 vs. the BMSC group. n=6 per group. BMSC, bone marrow stromal cell; Ch‑ABC, chondroitinase ABC; DMEM, Dulbecco's modified Eagle's medium; 
ANA, acellular nerve allograft; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; VEGF, vascular endothelial growth factor.
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NeuN, motoneuron marker (ChAT), SYP, and HRP retrograde 
labeled motoneurons and dendrites in the L5 spinal cord. It 
was revealed that the number of NeuN and ChAT-positive 
neurons and synaptophysin protein expression was signifi-
cantly increased in the Ch-ABC, BMSC and Ch-ABC + BMSC 
groups compared with the DMEM group at 8 weeks 
(P<0.05). Notably, the number of NeuN and ChAT-positive 
neurons, and synaptophysin-positive relative density in the 
Ch-ABC + BMSC group were much greater compared with 
the Ch-ABC group or the BMSC group (P<0.05; Fig. 8). 
Molecular indicators of neuronal growth and protection can 
be used to demonstrate the functional recovery of an artificial 
nerve alongside morphological indicators of axonal growth. 
Specifically, the motoneuron area, dendritic segment length 
Figure 5. Immunohistochemical staining of (A) NGF, (B) BDNF and (C) VEGF in the L4 spinal cord. 8 weeks after grafting (Scale bar=100 µm). (D) The numbers 
of positively stained neurons counted across sections of the spinal cord. All data are expressed as means ± standard deviation. *P<0.05, **P<0.05 vs. the DMEM 
group, #P<0.05, vs. the BMSC group. n=6 per group. BMSC, bone marrow stromal cell; Ch‑ABC, chondroitinase ABC; DMEM, Dulbecco's modified Eagle's 
medium; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; VEGF, vascular endothelial growth factor.
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and total dendritic length exhibited greater values in the BMSC, 
Ch-ABC and BMSC + Ch-ABC treated ANA compared with 
DMEM negative control. Thus, this further confirms previous 
results indicating that the BMSC + Ch-ABC group displayed 
significantly higher values compared with all other groups 
(P<0.05; Fig. 8). The results suggest that combined BMSCs 
and Ch-ABC treatment optimally protects motoneurons and 
enhances dendritic profiles following injury.
Combined treatment promotes the recovery of sciatic nerve 
function. At 8 weeks post-surgery, the conduction velocity 
(Fig. 9A), latency period (Fig. 9B) and wave amplitude (Fig. 9C) 
of the nerve graft were assessed by electrophysiology. The 
conduction velocity (Fig. 9A) and wave amplitude (Fig. 9C) 
were higher in all treatment groups compared with DMEM 
negative controls. Ch-ABC + BMSC combined treatment 
increased the values above BMSC or Ch-ABC alone (P<0.05). 
Figure 6. Immunohistochemical analysis of NGF, BDNF and VEGF in the anterior tibial muscles. 8 weeks after grafting, target muscle organ sections from each 
group were assessed for (A) NGF, (B) BDNF and (C) VEGF immunoreactivity (Scale bar=20 µm). (D) Relative density of positive signals. All data are expressed 
as means ± standard deviation. *P<0.05, **P<0.01 vs. the DMEM group; #P<0.05 vs. the BMSC group. n=6 per group. BMSC, bone marrow stromal cell; Ch-ABC, 
chondroitinase ABC; DMEM, Dulbecco's modified Eagle’s medium; NGF, nerve growth factor; BDNF, brain‑derived neurotrophic factor; VEGF, vascular 
endothelial growth factor.
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Conversely, the latency period (Fig. 9B) was decreased signifi-
cantly in all treatment groups compared with the DMEM 
control group (P<0.05). Furthermore, the latency period was 
decreased to a greater extent in the Ch-ABC + BMSC group 
compared with the Ch‑ABC and BMSC group (P<0.05). A final 
investigation of the recovery of tibialis anterior muscle weights 
(Fig. 9D) corroborated the effectiveness of either Ch-ABC or 
BMSC treatment while reinforcing that the combinatorial 
treatment supersedes the muscle recovery of either (P<0.05). 
These results support the hypothesis that while BMSC and 
Ch-ABC alone contributed to functional recovery of the nerve 
graft in vivo, the combination of the two therapies enhances 
the recovery rate significantly. 
Discussion
There is an increasing necessity in the field of PNI for therapies 
with improved long-term outcomes. Biologically, this equates 
to the requirement of novel and more efficacious methods of 
axonal regeneration. Recently, it has been demonstrated that 
the complex aberrations of PNI are better treated with a combi-
nation of peripheral nerve grafting and growth-promoting 
factors (such as stem cell transplantation and growth factor 
enhancement) (17). Despite improvements in functional 
and anatomical parameters of recovery, little is understood 
about the molecular drivers of combinatorial therapy such as 
Ch-ABC and BMSC-assisted ANA. Identifying the molecular 
growth cues of peripheral nerve regeneration, and how these 
may be enhanced by therapies such as stem cell transplantation 
and axonal growth factors may assist with the stratification 
of the adverse outcomes of nerve grafting, and guide future 
therapeutic intervention. Molecular, anatomical and functional 
parameters of peripheral nerve injury recovery were evaluated 
in the present study, subsequent to the establishment of a model 
of ANA pretreated with Ch-ABC and seeded with BMSCs.
BMSCs adhere tightly to donor ANA and stimulate the 
expression of NGF and BDNF growth factors in vitro. This 
signifies that even prior to surgery, the presence of multipotent 
stem cells is already enhancing the ability of the donor nerve 
to secrete growth-permissive factors (12). This ̔priming̓ may 
ultimately contribute to the biocompatibility of the donor graft 
to the recipient. BMSC seeding of the ANA serves to continu-
ally improve growth factor secretion in vivo with Ch-ABC 
significantly enhancing NGF, VEGF and BDNF secretion 
post-transplantation. The latter is likely due to the function of 
Ch-ABC as a remover of proteoglycan obstructions impeding 
axonal growth, and is a probable explanation for the absence of 
a Ch-ABC growth enhancement in vitro. 
To the best of our knowledge, the present study reports for 
the first time that BMSC and BMSC + Ch‑ABC treatments 
enhance the growth factor responses at distal sites of the ANA, 
at the spinal cord and target muscle, in a rat model of sciatic 
nerve gap. The patterns observed at distal sites reflect growth 
factor expression at the graft site, indicating that the propaga-
tion of growth cues occurs bidirectionally. Notably, retrograde 
axonal transport of growth factors, such as BDNF and NT-3, 
has previously been observed in spinal cord motoneurons with 
a distinct selectivity (18). Anterograde axonal transport of the 
neurotrophic factor, leukemia inhibitory factor, to denervated 
muscle was previously observed in a model of sciatic nerve 
transection (19), thus suggesting that neurotrophins such as 
BDNF, NGF and VEGF may also accumulate in target organs 
such as muscle. In 2001, von Bartheld et al (20) proposed several 
intricate, multi-step transfers of neurotrophic factors across 
neural circuits, a number of which may fit within the observed 
axonal anterograde transport and even reach dendritic fields. 
Ultimately, this bidirectional propagation of growth signals is 
likely an important contributor to the cellular and functional 
recovery observed after injury in previous BMSC + Ch-ABC 
treatment models (12). 
Combining the aforementioned data, the growth signal 
enhancement of the ANA, spinal cord and target muscle 
converge to guide axonal regeneration, neuronal protection 
and functional recovery. 
The synergistic effect of local and distal growth signaling 
manifest therapeutic benefits, such as the observed nerve 
fiber growth that occurs on the ANA, up to 8 weeks after 
grafting (Fig. 3). Additionally, spinal cord motoneurons 
benefit through increased expression of mature neuronal 
markers and motoneuron specifiers (Fig. 5). The indicated 
increase in motoneuron survival has previously been observed 
in intramuscular stem cell transplantation models, suggesting 
that spinal cord motoneuron survival is assisted by growth 
factor-secreting stem cells acting locally (21), or as far as target 
muscular regions (22). It is plausible then, that BMSC and 
BMSC + Ch-ABC, promoting growth factor secretion at local 
Figure 7. mRNA expression of NGF, BDNF and VEGF. 8 weeks after grafting, (A) ANA, (B) spinal cord and (C) anterior tibial muscles were extracted from 
all treatment groups for quantitation of NGF, BDNF and VEGF relative expression . mRNA expression was determined by reverse transcription-quantitative 
polymerase chain reaction. All data are expressed as means ± standard deviation. *P<0.05, **P<0.01, ***P<0.001, vs. the DMEM group; #P<0.05, vs. the BMSC 
group; (n=6). BMSC, bone marrow stromal cell; Ch‑ABC, chondroitinase ABC; DMEM, Dulbecco's modified Eagle's medium; NGF, nerve growth factor; 
BDNF, brain-derived neurotrophic factor; VEGF, vascular endothelial growth factor.
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Figure 8. Motoneuron survival and dentritogenesis in the L4 spinal cord 8 weeks after graft: (A) Immunohistochemical staining of NeuN (Scale bar=100 µm), 
ChAT (Scale bar=20 µm) and synaptophysin (Scale bar=20 µm). DAPI nuclear counterstain (blue) was performed on L4 spinal cord sections across treatment 
groups using fluorescent reporters. Below, horseradish peroxidase retrograde tracing of motoneuron dendrites in the L4 spinal cord (Scale bar=100 µm) were 
generated by injection with B‑horseradish peroxidase 4 weeks after injury (analyzed 48 h after injection). Polar histograms of dendritic fields were generated by 
computer morphometry system across the various groups. Numbers of (B) NeuN and (C) ChAT-positively stained neurons are counted and in (D) synaptophysin 
relative density of the spinal cord is displayed. (E) Area of motoneurons is displayed, and (F) the segment lengths of the motoneuron dendrites as well as total 
dendritic lengths (G) are also presented. Data are expressed as means ± standard deviation; *P<0.05, **P<0.01, ***P<0.001, vs. the DMEM group. #P<0.05, ##P<0.01, 
###P<0.001, vs. the BMSC group. n=6 per group). BMSC, bone marrow stromal cell; Ch‑ABC, chondroitinase ABC; DMEM, Dulbecco's modified Eagle's medium; 
ChAT, choline acetyltransferase; NeuN, neuronal marker.
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and/or distal ends of the allograft, are similarly supporting 
motoneuron survival.
Furthermore, the use of combinatorial ANA therapies 
administered in the current study indicated that synaptic 
profiles of motoneuron dendrites were markedly improved 
(Fig. 8). Similarly, the synaptic protein synaptophysin is 
enhanced by BMSC + Ch-ABC treatment. Retrograde trans-
port of neurotrophic factors such as BDNF has previously 
demonstrated the capacity to reach motoneruonal synaptic 
sites through a process called transsynaptic transcytosis (23), 
activating a cascade of synaptic plasticity signals. Another 
previous study reported that mesenchymal stem cell secre-
tion of BDNF and GDNF at spinal motoneuron sites aided 
synaptophysin-positive nerve terminal preservation (24) and 
motoneuron synaptogenesis (21). Ultimately, survival and 
synaptogenesis of the motoneuron are critical to functional 
reinnervation of target tissue, and molecular mechanisms such 
as those used in the model in the current study likely enhance 
functional recovery.
Functional parameters of axonal regeneration have been 
previously demonstrated in our BMSC + Ch-ABC model of 
ANA (8); however, the molecular underpinnings had yet to 
be elucidated. In the current study, it was revealed that elec-
trophysiological measures of recovered nerve function are 
improved, likely as an effect of the local and retro/anterograde 
transport of BMSC-assisted growth factors (Fig. 9). In addition, 
removal of proteoglycan obstructions by Ch-ABC contributes 
to an enhanced functional recovery. The mechanism by which 
growth signals trigger axonal regeneration remains subject 
to debate. Live, long-term imaging of axonal lesions has 
demonstrated that growth factors such as BDNF are able to 
promote cytoskeletal elements responsible for cell growth (25). 
Specifically, the number and rate of actin ̔waves̓ that form 
the microfilaments responsible for axonal morphogenesis and 
pathfinding, are enhanced by the introduction of BDNF (26). 
Finally, the present study reported that the restoration 
of target muscle mass is innervated by axotomized nerves. 
Muscular growth and reinnervation are critical components of 
functional recovery from PNI. Graft site stimulation of growth 
cues were anterogradely propagated to muscle targets. Gene 
manipulation-derived delivery of the growth factor VEGF 
has previously been demonstrated to aid in peripheral nerve 
regeneration through the enhancement of nerve reinnervation 
and axonal diameter growth (27). Similarly, VEGF interven-
tion in a PNI model demonstrated that denervated muscle 
atrophy was significantly slowed, although VEGF overexpres-
sion led to worse nerve regeneration compared with negative 
controls (28). 
Notably, although Ch-ABC and BMSC contributed to the 
functional recovery of the nerve, the combination of the two 
outweighed the therapeutic benefit of each treatment individu-
ally in almost all parameters of morphological and functional 
recovery assessed by the current study. This effect is enduring 
and abounds not only in the graft site but extends to both 
distal regions where the target muscle and motoneurons also 
demonstrate therapeutic phenomena. In the current study, the 
first reported comprehensive molecular examination of the 
BMSC + Ch-ABC ANA in an in vivo model of sciatic nerve 
gap was attempted. It was determined that the combination 
therapy enhances the growth response of the nerve, however, 
also appears to stimulate the growth response of the target 
organ and motoneurons. The aforementioned wide-reaching 
stimulation of growth factors ultimately contributes to func-
tional repair of not only the nerve, but also the protection of 
the motoneuron and the growth of the target muscle. 
Although the current study improved our understanding 
of the molecular cues guiding nerve regeneration in 
Ch-ABC + BMSC ANA repair, the method by which growth 
signals are propagated to the distal ends of the graft remains 
unclear. We propose retro- and anterograde transport pathways 
as a plausible means of growth signal propagation, though 
a thorough examination of these mechanisms remains to be 
performed. Furthermore, the convergence of distal and local 
growth signals render it difficult to reveal the exact method by 
Figure 9. Electrophysiological index and tibialis anterior muscle recovery. (A) Conduction velocity, (B) latency period, (C) wave amplitude of the nerve graft 
were assessed by electrophysiology prior to sacrifice (8 weeks after graft). (D) Recovery assessment of tibialis anterior muscle was also indicated by the weight 
ratio of muscle from operated side to the muscle weight of the un-operated (contralateral) side. All data expressed as mean ± standard deviation. *P<0.05, 
**P<0.01, ***P<0.001, vs. the DMEM group; #P<0.05, vs. the BMSC group; (n=8 per group). BMSC, bone marrow stromal cell; Ch-ABC, chondroitinase ABC; 
DMEM, Dulbecco's modified Eagle's medium; NGF, nerve growth factor; BDNF, brain‑derived neurotrophic factor; VEGF, vascular endothelial growth factor.
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which each signaling source is mechanistically associated with 
individual parameters of post-graft recovery. It will be impor-
tant in the future to analyze these independently to better gauge 
how each signaling source specifically contributes to cellular 
and functional aspects of recovery. Investigation of growth 
factor-activated downstream signaling is also important to 
further understand the exact signaling pathways that mediate 
anatomical and functional restoration such as neurite growth. 
Pharmacological manipulation and time-course designs are 
potential approaches to further investigate the results reported 
in the current study. Despite limitations, it is clear that an 
understanding of how BMSCs and Ch-ABC mediate growth 
signaling affects and enhance donor nerve growth cues is a 
step toward optimizing the combinatorial therapy that has to 
date demonstrated marked efficacy. This endeavor is worth-
while as a full functional recovery of peripheral nerve injury 
remains to be achieved. 
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